Journal of the American College of Cardiology
Volume 72, Issue 23, Part A, 11 December 2018, Pages 2886-2903
The Present and FutureJACC State-of-the-Art ReviewMedical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review
JACC State-of-the-Art Review
Under an Elsevier user license
open archive
Central Illustration
Key Words
atherosclerosis
cholesterol
inflammation
post-MI stable coronary artery disease
residual risk
thrombosis
Abbreviations and Acronyms
ACS
acute coronary syndrome
CAD
coronary artery disease
CRP
C-reactive protein
DAPT
dual antiplatelet therapy
GDMT
guideline-directed medical therapy
LDL-C
low-density lipoprotein cholesterol
MACE
major adverse cardiac events
MI
myocardial infarction
PCI
percutaneous coronary intervention
RCT
randomized controlled trial
Cited by (0)
Dr. Libby has served as an unpaid consultant for Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Sanofi-Regeneron, and XBiotech, Inc.; has served on the scientific advisory board of Corvidia Therapeutics, Olatec Therapeutics, and Medimmune; and has received laboratory funding from Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
© 2018 Published by Elsevier on behalf of the American College of Cardiology Foundation